PDI, Align Pharmaceuticals form agreement to commercialize cancer products

By Angela McDaniels

Seattle, Jan. 19 - PDI Inc. said it has entered into a three-year agreement with Align Pharmaceuticals to help commercialize Align's new oncology products.

PDI will initially provide a sales team of 40 field representatives to oversee the sales of three oncology products recently acquired by Align: Numoisyn Lozenges and Numoisyn Liquid, for the treatment of dry mouth caused by radiation therapy or Sjogren's Syndrome, and Xclair, for the treatment of radiation dermatitis.

"We were looking for a strategic partner to help us build a company that can win in the marketplace without building our own infrastructure," Align chief executive officer Bill Collins said in a company news release.

"PDI's history of building effective specialty teams, coupled with their capabilities in medical education and marketing research, precisely matched our needs in launching our commercialization effort."

PDI, based in Saddle River, N.J., provides sales and marketing services to the biopharmaceutical industry.

Align is an emerging biopharmaceutical company based in Cary, N.C., that markets recently approved biopharmaceuticals.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.